# Theracos

Organization · id `cardio:org-theracos` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Theracos>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 7 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Theracos
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus (`cardio:ct-nct02390050`)
- Sponsors: Bexagliflozin Efficacy and Safety Trial (`cardio:ct-nct02558296`)
- Sponsors: Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes (`cardio:ct-nct02715258`)
- Sponsors: Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (`cardio:ct-nct02769481`)
- Sponsors: Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment (`cardio:ct-nct02836873`)
- Sponsors: Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (`cardio:ct-nct03115112`)
- Sponsors: An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension (`cardio:ct-nct03514641`)

## Provenance

Content hash: cdd4957e279dafd68ce082f584514e1d9d859e7532d178582028664e3b461638
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
